Literature DB >> 18775558

Primary pelvic exenteration in cervical cancer patients.

Laszlo Ungar1, Laszlo Palfalvi, Zoltan Novak.   

Abstract

Despite the reports of a number of leading institutions concerning the use of primary exenteration, there are differences in regard to definition, indications, and interpretation of results of this treatment approach to cervical cancer. In this paper we present our own experience with 41 cervical cancer patients treated with primary exenteration at St. Stephen Hospital Budapest. We explore some important unsettled aspects (definition, indications, and quality of life consequences) of this treatment modality in view of our own experience and the literature. Between January 1993 and June 2006, 2540 invasive cervical cancer patients were seen at the gynecologic oncology service of the St. Stephens Hospital Budapest. Two hundred twelve (8%) of these patients were surgically explored with the plan of an exenterative surgery. Exenteration was the primary treatment in 41 (25%) of 166 completed exenterations; these 41 cases included 2 cases of supralevator total exenteration, 9 cases of supralevator anterior exenteration, and 30 cases of partial supralevator anterior exenteration. In the 2 total exenteration patients, anal function was restored with a low rectal anastomosis, with a temporary defunctioning colostomy in 1 patient. Urethral function was restored in 9 out of 11 supralevator exenteration cases with the Budapest pouch bladder replacement technique. In the remaining 2 cases, a Bricker conduit was used for urinary diversion. There was no operation-related mortality in this cohort of patients. An external fecal or urinary stoma was avoided in 38 (93%) out of the 41 primary exenteration patients; in 1 patient a temporary defunctioning colostomy was used; and in 2 patients a permanent ileal conduit was created. In 9 patients (22%), complications (ileus and peritonitis, occlusion of the femoral artery, stricture of the implanted ureter, and postoperative ureterovaginal fistula) necessitated surgical intervention. A quality of life study revealed the need for prolonged self-catheterization, partial (mainly night time) incontinence, and lymphedema in 7 patients. We consider and suggest that an en bloc resection of part(s) of the urinary bladder and/or the rectum with the uterine cervix should be considered an exenteration (partial exenteration). A 50% survival rate of a select group of stage IVA cervical cancer patients treated with primary exenteration can be considered significant, but cannot be considered superior to that of chemoradiation therapy. The same applies when considering treatment-related mortality and complications that require operative interventions. Low rectal anastomosis and orthotopic bladder replacement with a relative low risk of fistula formation in non-irradiated patients constitute a strong quality of life argument in favor of primary exenteration in a select group of stage IVA cervical cancer patients.

Entities:  

Mesh:

Year:  2008        PMID: 18775558     DOI: 10.1016/j.ygyno.2008.07.041

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Pelvic exenteration for the treatment of locally advanced colorectal and bladder malignancies in the modern era.

Authors:  Paul J Speicher; Ryan S Turley; Jason L Sloane; Christopher R Mantyh; John Migaly
Journal:  J Gastrointest Surg       Date:  2013-11-08       Impact factor: 3.452

2.  Outcome of Patients with Cervical and Vaginal Stump Carcinomas Treated with More Conservative Surgical Approaches: a 9-Year Experience of a Tertiary Oncology Center.

Authors:  Mohamed Hegazy; Ashraf Khater; Mohamed Awad; Sherif Kotb; Waleed Elnahas; Sameh Roshdy; Osama Eldamshety; Fayez Shahatto; Omar Farouk; Emadeldeen Hamed; Refaat Hegazi; Ola T Abdel Dayem; Anas M Gamal
Journal:  Indian J Surg Oncol       Date:  2017-03-11

3.  A prospective study of quality of life in patients undergoing pelvic exenteration: interim results.

Authors:  Youssef A Rezk; Karen E Hurley; Jeanne Carter; Fanny Dao; Bernard H Bochner; Janice J Aubey; Aileen Caceres; M Heather Einstein; Nadeem R Abu-Rustum; Richard R Barakat; Vicky Makker; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2012-10-09       Impact factor: 5.482

Review 4.  Pelvic exenteration--reconsidering the procedure.

Authors:  N Bacalbasa; I Balescu
Journal:  J Med Life       Date:  2015 Apr-Jun

Review 5.  Image-Guided Brachytherapy for Salvage Reirradiation: A Systematic Review.

Authors:  Sophie Bockel; Sophie Espenel; Roger Sun; Isabelle Dumas; Sébastien Gouy; Philippe Morice; Cyrus Chargari
Journal:  Cancers (Basel)       Date:  2021-03-11       Impact factor: 6.639

6.  The impact of nutritional risk factors and sarcopenia on survival in patients treated with pelvic exenteration for recurrent gynaecological malignancy: a retrospective cohort study.

Authors:  Veronika Seebacher; Andrea Rockall; Marielle Nobbenhuis; S Aslam Sohaib; Thomas Knogler; Rosa M Alvarez; Desiree Kolomainen; John H Shepherd; Clare Shaw; Desmond P Barton
Journal:  Arch Gynecol Obstet       Date:  2021-11-03       Impact factor: 2.344

7.  Surgical results of pelvic exenteration in the treatment of gynecologic cancer.

Authors:  Andrea Petruzziello; William Kondo; Sergio B Hatschback; João A Guerreiro; Flávio Panegalli Filho; Cristiano Vendrame; Murilo Luz; Reitan Ribeiro
Journal:  World J Surg Oncol       Date:  2014-09-08       Impact factor: 2.754

8.  Analysis of long-term outcomes in 44 patients following pelvic exenteration due to cervical cancer.

Authors:  Agnieszka Lewandowska; Sebastian Szubert; Krzysztof Koper; Agnieszka Koper; Grzegorz Cwynar; Lukasz Wicherek
Journal:  World J Surg Oncol       Date:  2020-09-02       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.